Citi upgrades CME Group to Buy on near-term catalysts

Citi upgraded CME Group (CME) to Buy from Neutral with a price target of $300, up from $275. Citi also placed an “upside 90-day catalyst watch” on the shares. The firm sees catalysts ahead for the shares from U.S. Treasury clearing, the OSTTRA joint venture, the Fanduel partnership, and annual variable dividend announcement. CME offers a “robust” capital return outlook over the next four months, the analyst tells investors in a research note.